About us
Our Story
provide deeper efficacy and more overall benefits to patients
Focus
Safety
For patients & society
• Completed phase I clinical trial of ABSK091 in Taiwan and commenced phase 1b/II trial in mainland China
• Completed phase Ia clinical trial and ABSK021 in the US and initiated the expansion studies
• Commenced phase 1b trial of ABSK011 in China
• Commenced phase 1b trial of ABSK081 in China
• Obtained clinical approval for conducting phase 1 study of ABSK043 in Australia
• Completed series D financing of US$123 million
• Obtained IND approval from the NMPA to conduct its Phase Ib/II clinical trial of ABSK081 in mainland China
• Completed our series C financing of $42 million led by Temasek
• Commenced the Phase Ia clinical trial of ABSK021 in the United States
• Commenced the Phase Ia clinical trial of ABSK011 in the Taiwan
• Obtained IND approval from the NMPA to conduct its Phase Ib/II clinical trial of ABSK091 in mainland China
• Completed series B financing of $42 million led by Qiming Venture Partners
• Obtained IND approval from NMPA for ABSK011
• Obtained IND approval from FDA for ABSK021
• In-licensed ABSK091 from AstraZeneca with global rights and ABSK081 from X4 Therapeutics with greater China rights
• Selected the second PCC ABSK021, a highly potent and selective CSF-1R inhibitor
• Opened the 4000m2 R&D center in Zhangjiang Hi-Tech Park, Shanghai, China
• Completed series A financing of $28 million led by Lilly Asia Venture
• Selected our first PCC (pre-clinical candidate) ABSK011 for treating HCC and other cancers
• Our company was established in the Zhangjiang Hi-Tech Park, Shanghai, China.
• We started our first two drug discovery programs, ABSK011 and ABSK021.
• Our company was established in the Zhangjiang Hi-Tech Park, Shanghai, China.
• We started our first two drug discovery programs, ABSK011 and ABSK021.
• Completed series A financing of $28 million led by Lilly Asia Venture
• Selected our first PCC (pre-clinical candidate) ABSK011 for treating HCC and other cancers
• Selected the second PCC ABSK021, a highly potent and selective CSF-1R inhibitor
• Opened the 4000m2 R&D center in Zhangjiang Hi-Tech Park, Shanghai, China
• Completed series B financing of $42 million led by Qiming Venture Partners
• Obtained IND approval from NMPA for ABSK011
• Obtained IND approval from FDA for ABSK021
• In-licensed ABSK091 from AstraZeneca with global rights and ABSK081 from X4 Therapeutics with greater China rights
• Commenced the Phase Ia clinical trial of ABSK021 in the United States
• Commenced the Phase Ia clinical trial of ABSK011 in the Taiwan
• Obtained IND approval from the NMPA to conduct its Phase Ib/II clinical trial of ABSK091 in mainland China
• Obtained IND approval from the NMPA to conduct its Phase Ib/II clinical trial of ABSK081 in mainland China
• Completed our series C financing of $42 million led by Temasek
• Commenced phase 1b trial of ABSK011 in China
• Commenced phase 1b trial of ABSK081 in China
• Obtained clinical approval for conducting phase 1 study of ABSK043 in Australia
• Completed series D financing of US$123 million
• Completed phase I clinical trial of ABSK091 in Taiwan and commenced phase 1b/II trial in mainland China
• Completed phase Ia clinical trial and ABSK021 in the US and initiated the expansion studies
Leveraging the experience of our R&D team, we have built a multi-dimensional and innovation-driven discovery platform with comprehensive capabilities in cancer genomics and screening, computational and medicinal chemistry, and translational and biomarker science,which enables us to discover high-quality assets with efficiency.
Copyright © 2021 All rights reserved:Abbisko Therapeautics 沪ICP备17056565号-1